Cerivastatin for lowering lipids
نویسندگان
چکیده
منابع مشابه
Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.
OBJECTIVES We investigated whether improvement of endothelial dysfunction in hypercholesterolemia can be achieved with short-term lipid-lowering therapy. BACKGROUND Impaired endothelium-dependent vasodilation plays a pivotal role in the pathogenesis of atherosclerosis and acute coronary syndromes. METHODS In a randomized, double-blind, placebo-controlled trial, we studied 37 patients (52 +/...
متن کاملTargets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People
Improving cardiovascular (CV) risk profile, by lowering elevated body weight, blood pressure (BP), plasma cholesterol, and blood glucose (BG) levels, is of relevance for decreasing fatal and nonfatal CV events in young and middleaged patients (1–4). Evidence also exists that the above-mentioned interventions are also highly effective in older patients, i.e., in subjects .65 years of age (3–6). ...
متن کاملWithdrawal of cerivastatin from the world market
Cerivastatin was recently withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure. The risk was found to be higher among patients who received the full dose (0.8 mg/day) and those who received gemfibrozil concomitantly. Rhabdomyolysis was 10 times more common with cerivastatin than the other five approved statins. We address three imp...
متن کاملSerum lipids, lipid-lowering drugs, and the risk of breast cancer.
BACKGROUND Experimental evidence suggests that statins protect against breast carcinogenesis by interrupting cell cycle progression and promoting apoptosis. Evidence in humans is limited and inconsistent. The relation between serum cholesterol levels and breast cancer risk is itself unclear; because cholesterol is the precursor to sex steroid hormones, higher levels could plausibly increase ris...
متن کاملMonitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy
A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be bett...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2020
ISSN: 1465-1858
DOI: 10.1002/14651858.cd012501.pub2